Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-78c5997874-lj6df Total loading time: 0 Render date: 2024-11-06T10:14:15.953Z Has data issue: false hasContentIssue false

14 - Adjuvant analgesic drugs

from SECTION IV - PHARMACOLOGICAL TREATMENT

Published online by Cambridge University Press:  06 July 2010

By
RUSSELL K. PORTENOY  and
MERVYN KOH
Edited by
Eduardo D. Bruera  and
Russell K. Portenoy
RUSSELL K. PORTENOY
Affiliation:
Beth Israel Medical Center and Albert Einstein College of Medicine
MERVYN KOH
Affiliation:
Tan Tock Seng Hospital
Eduardo D. Bruera
Affiliation:
University of Texas, Houston
Russell K. Portenoy
Affiliation:
Albert Einstein College of Medicine, New York
Get access

Summary

Introduction

The term adjuvant analgesic was originally coined to refer to a small number of drugs that were commercialized for reasons other than pain but could be used as analgesics in selected circumstances. When these nontraditional analgesics were prescribed to cancer patients to supplement the analgesia provided by opioids, they were considered to be adjuvant to the mainstay therapy – hence the term. In recent years, the number, diversity, and conventional use of these nontraditional analgesics have increased dramatically. Several are now indicated and promoted for specific types of noncancer pain and many are used as first-line therapies in varied populations. Accordingly, the term adjuvant analgesic is now a commonly applied misnomer and refers to a large and diverse group of drugs that have an expanding role in pain medicine.

In the management of cancer pain, the term adjuvant analgesic also must be distinguished from other labels, specifically adjuvant drug and co-analgesic. According to the three-step analgesic ladder model of cancer pain pharmacotherapy developed under the auspices of the World Health Organization in the mid-1980s, adjuvant drugs comprise both analgesics used to supplement opioid therapy (adjuvant analgesics) and drugs used to manage the side effects of the opioids. Given this dual labeling, the drugs intended to provide analgesia are best denoted by the more specific term adjuvant analgesics. The label co-analgesic has been used synonymously with adjuvant analgesic in the cancer treatment setting and also could be used whenever referring to a drug added for analgesic purposes to an existing opioid regimen.

Type
Chapter
Information
Cancer Pain
Assessment and Management
 , pp. 272 - 286
Publisher: Cambridge University Press
Print publication year: 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Lussier, D, Portenoy, RK. Adjuvant analgesics. In: Hanks, G, Cherny, N, Kaasa, S, et al., eds. Oxford textbook of palliative medicine, 4th ed. Oxford: Oxford University Press, 2009.Google Scholar
,World Health Organization. Cancer pain relief and palliative care. Geneva: World Health Organization, 1990.Google Scholar
Bruera, E, Roca, E, Cedaro, L, et al. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 69:751–4, 1985.Google ScholarPubMed
Della Cuna, GR, Pellegrini, A, Piazzi, M. Effect of methylprednisolone sodium succinate on quality of life in preterminal cancer patients: a placebo-controlled, multicenter study. The Methylprednisolone Preterminal Cancer Study Group. Eur J Cancer 25:1817–21, 1989.Google ScholarPubMed
Tannock, I, Gospodarowicz, M, Meakin, W, et al. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 7:590–7, 1989.CrossRefGoogle Scholar
Hanks, GW, Trueman, T, Twycross, RG. Corticosteroids in terminal cancer: a prospective analysis of current practice. Postgrad Med J 59:702–6, 1983.CrossRefGoogle ScholarPubMed
Mercadante, SL, Berchovich, M, Casuccio, A, et al. A prospective randomized study of corticosteroids as adjuvant drugs to opioids in advanced cancer patients. Am J Hosp Palliat Care 24:13–19, 2007.CrossRefGoogle ScholarPubMed
Loblaw, DA, Perry, J, Chambers, A. Systematic review of the diagnosis and management of malignant extradural spinal cord compression: the Cancer Care Ontario Practice Guidelines Initiative's Neuro-Oncology Disease Site Group. J Clin Oncol 23:2028–37, 2005.CrossRefGoogle ScholarPubMed
Sørensen, S, Helweg-Larsen, S, Mouridsen, H. Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial. Eur J Cancer 30A:22–7, 1994.CrossRefGoogle ScholarPubMed
Dworkin, RH, O'Connor, AB, Backonja, M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 132:237–51, 2007.CrossRefGoogle ScholarPubMed
Paolo, F, Darcourt, G, Corsa, P. Note preliminaire sur l'action de l'imipraminedans les estats douloureux. Rev Neurol 2:503–4, 1960.Google Scholar
Ventafridda, V, Bonezzi, C, Caraceni, A, et al. Antidepressants for cancer pain and other painful syndromes with deafferentation component: comparison of amitriptyline and trazodone. Ital J Neurol Sci 8:579–87, 1987.CrossRefGoogle ScholarPubMed
Davis, MP. What is new in neuropathic pain?Support Care Cancer 15:363–72, 2007.CrossRefGoogle ScholarPubMed
Grond, S, Radbruch, L, Meuser, T. Assessment and treatment of neuropathic cancer pain following WHO guidelines. Pain 79:15–20, 1999.CrossRefGoogle ScholarPubMed
Berger, S, Mercadante, S, Oster, G. Use of antiepileptics and tricyclic antidepressants in cancer with neuropathic pain. Eur J Cancer Care 15:138–45, 2006.CrossRefGoogle ScholarPubMed
Pancrazio, JJ, Kamatchi, GL, Roscoe, AK. Inhibition of neuronal Na+ channels by antidepressant drugsJ Pharmacol Exp Therap 284:208–14, 1998.Google ScholarPubMed
Shimizu, M, Nishida, A, Yamawaki, S. Antidepressants inhibit spontaneous oscillations of intracellular Ca2+ concentration in rat cortical cultured neurons. Neurosci. Lett 146:101–4, 1992.Google Scholar
Sindrup, SH, Gram, LF, Skjold, T, et al. Concentration-response relationship in imipramine treatment of diabetic neuropathy symptoms. Clin Pharmacol Ther 47:509–15, 1990.CrossRefGoogle ScholarPubMed
Max, MB, Lynch, SA, Muir, J, et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 326:1250–6, 1992.CrossRefGoogle ScholarPubMed
Sindrup, SH, Gram, LF, Brosen, K. The SSRI paroxetine is effective in the treatment of diabetic peripheral neuropathy symptoms. Pain 42:135–44, 1990.CrossRefGoogle Scholar
Sindrup, SH, Bjerre, U, Dejgaard, A. The SSRI citalopram relieves the symptoms of diabetic neuropathy. Clin Pharm Ther 52:547–52, 1992.CrossRefGoogle ScholarPubMed
Rowbotham, MC, Goli, V, Kunz, NR. Venlafaxine extended release in the treatment of painful diabetic neuropathy. Pain 110:697–706, 2004.CrossRefGoogle ScholarPubMed
Sindrup, SH, Bach, FW, Madsen, C. Venlafaxine versus imipramine in painful polyneuropathy. Neurology 60:1284–9, 2003.CrossRefGoogle ScholarPubMed
Wernicke, JF, Pritchett, YL, D'Souza, DN. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 67:1411–20, 2006.CrossRefGoogle ScholarPubMed
Arnold, LM, Rosen, A, Pritchett, YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 119:5–15, 2005.CrossRefGoogle ScholarPubMed
Gendreau, RM, Thorn, MD, Gendreau, JF, et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 32:1975–85, 2005.Google ScholarPubMed
Sindrup, SH, Bach, FW, Madsen, C, et al. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology 60:1284–9, 2003.CrossRefGoogle ScholarPubMed
Dunner, DL, Wohlreigh, MM, Mallingkrodt, CH. Clinical consequences of initial duloxetine dosing strategies; Comparison of 30 and 60 mg starting doses. Curr Ther Res 66:1–19, 2005.CrossRefGoogle ScholarPubMed
Semenchuk, MR, Sherman, S, Davis, B. Double blind, randomized trial of bupropion SR for the treatment of neuropathic pain. Neurology 57:1583–8, 2001.CrossRefGoogle ScholarPubMed
Theobald, , Kirsh, KL, Holtsclaw, E. An open-label crossover trial of mirtazepine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J Pain Symptom Manage 23:442–7, 2002.CrossRefGoogle Scholar
Serpell, MG. Gabapentin in neuropathic pain syndromes: a randomized, double-blinded, placebo-controlled trial. Pain 99:557–66, 2002.CrossRefGoogle Scholar
Backonja, M, Beydoun, A, Edwards, KR. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus. JAMA 280:1831–6, 1999.CrossRefGoogle Scholar
Rowbotham, M, Harden, N, Stacey, B. Gabapentin for the treatment of postherpetic neuralgia. JAMA 280:1837–42, 1998.CrossRefGoogle ScholarPubMed
Caraceni, A, Zecca, E, Bonezzi, C. Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol 32:2909–17, 2004.CrossRefGoogle Scholar
Frampton, JE, Foster, RH. Pregabalin in the treatment of postherpetic neuralgia. Drugs 65:111–18, 2005.CrossRefGoogle ScholarPubMed
Dworkin, RH, Corbin, AE, Young, JP. Pregabalin for the treatment of postherpetic neuralgia: a randomized placebo-controlled trial. Neurology 60:1274–83, 2003.CrossRefGoogle ScholarPubMed
Rosenstock, J, Tuchman, M, LaMoreaux, L, Sharma, U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double blind placebo-controlled trial. Pain 110:628–38, 2004.CrossRefGoogle ScholarPubMed
Lesser, H, Sharma, U, LaMoreaux, L, Poole, RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 63:2104–10, 2004.CrossRefGoogle ScholarPubMed
Richter, RW, Portenoy, R, Sharma, U. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized placebo controlled trial. J Pain 6:253–60, 2005.CrossRefGoogle ScholarPubMed
Gore, M, Sadosky, A, Tai, KS, Stacey, B. A retrospective evaluation of the use of gabapentin and pregabalin in patients with postherpetic neuralgia in usual care settings. Clin Ther 29:1655–70, 2007.CrossRefGoogle ScholarPubMed
Eisenberg, E, River, Y, Shifrin, A. Antiepileptic drugs in the treatment of neuropathic pain. Drugs 67:1265–89, 2007.CrossRefGoogle ScholarPubMed
Rockliff, BW, Davis, EH. Controlled sequential trials of carbamazepine in trigeminal neuralgia. Arch Neurol 15:129–36, 1966.CrossRefGoogle ScholarPubMed
Leijon, G, Boivie, J. Central post-stroke pain: a controlled trial of amitriptyline and carbamazepine. Pain 36:27–36, 1989.CrossRefGoogle ScholarPubMed
Otto, M, Bach, FW, Jensen, TS. Valproic acid has no effect on pain in polyneuropathy; a randomized controlled trial. Neurology 62:285–8, 2004.CrossRefGoogle ScholarPubMed
Kochar, DK, Gark, P, Bumb, RA, et al. Divalproex sodium in the management of postherpetic neuralgia: a randomized double-blinded placebo controlled study. QJM 98:29–34, 2005.CrossRefGoogle Scholar
Chadda, VS, Mathur, M. Double-blind study of the effects of diphenylhydantoin sodium on diabetic neuropathy. J Assoc Physicians India 26:403–6, 1978.Google ScholarPubMed
Saudek, CD, Werns, S, Reidenberg, MM. Phenytoin in the treatment of diabetic symmetrical neuropathy. Clin Pharm Ther 22:196–9, 1977.CrossRefGoogle Scholar
Hugel, H, Ellershaw, JE, Dickman, A. Clonazepam as an adjunct analgesic in patients with cancer-related neuropathic pain. J Pain Symptom Manage 26:1073–4, 2003.CrossRefGoogle Scholar
Fernandez, F, Adams, F, Holmes, VF. Analgesic effect of alprazolam in patients with chronic, organic pain of malignant origin. J Clin Psychopharmacol 7:167–9, 1987.CrossRefGoogle ScholarPubMed
Wiffen, PJ, Rees, J. Lamotrigine for acute and chronic pain. Cochrane Rev CD:00075320, 2007.
Thienel, U, Neto, W, Schwabe, SK. Topiramate in painful diabetic polyneuropathy: findings from 3 double-blinded placebo-controlled trials. Acta Neurol Scand 110:221–31, 2004.Google Scholar
Raskin, P, Donofrio, PD, Rosenthal, NR. Topiramate vs placebo in painful diabetic neuropathy: analgesic and metabolic effects. Neurology 63:865–73, 2004.CrossRefGoogle ScholarPubMed
Khoromi, S, Patsalides, A, Parada, S. Topiramate in chronic lumbar radicular pain. J Pain 6:829–36, 2005.CrossRefGoogle ScholarPubMed
Gilron, I, Booher, SL, Rowan, JS. Topiramate in trigeminal neuralgia: a randomized, placebo-controlled multiple cross-over pilot study. Clin Neuropharmacol 24:109–12, 2001.CrossRefGoogle Scholar
Nassreddine, W, Beydoun, A. Oxcarbazepine in neuropathic pain. Exp Opin Invest Drugs 16:1615–25, 2007.CrossRefGoogle Scholar
Todorov, AA, Kolchev, CB, Todorov, AB. Tiagabine and gabapentin for the management of chronic pain. Clin J Pain 21:358–61, 2005.CrossRefGoogle ScholarPubMed
Rowbotham, MC, Manville, NS, Ren, J. Pilot tolerability and effectiveness study of levetiracetam for postherpetic neuralgia. Neurology 61:866–7, 2003.CrossRefGoogle ScholarPubMed
Vilholm, OJ, Cold, S, Rasmussen, L, Sindrup, SH. Effect of levetiracetam on the postmastectomy pain syndrome. Eur J Neurol 15:851–7, 2008.CrossRefGoogle ScholarPubMed
Atli, A, Dogra, S. Zonisamide in the treatment of painful diabetic neuropathy: a randomized double-blinded, placebo-controlled pilot study. Pain Med 6:225–34, 2005.CrossRefGoogle Scholar
Byas-Smith, MG, Max, MB, Muir, J. Transdermal clonidine compared to placebo in painful diabetic neuropathy using a two-stage “enriched enrollment” design. Pain 610:267–74, 1995.CrossRefGoogle Scholar
Fogelholm, R, Murros, K. Tizanidine in chronic tension-type headache: a placebo-controlled, double-blind cross-over study. Headache 32:509–13, 1992.CrossRefGoogle Scholar
Eisenach, JC, DuPen, S, Dubois, M. Epidural clonidine analgesia for intractable cancer pain. The Epidural Clonidine Study Group. Pain 61:391–400, 1995.CrossRefGoogle ScholarPubMed
Fromm, GH, Terrence, CF, Chattha, AS. Baclofen in the treatment of trigeminal neuralgia: double-blind study and long-term follow-up. Ann Neurol 15:240–4, 1984.CrossRefGoogle ScholarPubMed
Tremont-Lukats, IW, Challapalli, V, McNicol, ED. Systematic administration of local anesthetics to relieve neuropathic pain: a systematic review and meta-analysis. Anesth Analg 101:1738–49, 2005.CrossRefGoogle ScholarPubMed
Challapalli, V, Tremont-Lukats, IW, McNicol, ED, et al. Systemic administration of local anesthetic agents to relieve neuropathic pain. Cochrane Database Syst Rev CD003345, 2005.
Lindstrom, P, Lindblom, U. The analgesic effect of tocainide in trigeminal neuralgia. Pain 28:45–50, 1987.CrossRefGoogle ScholarPubMed
Dejgard, A, Petersen, P, Kastrup, J. Mexiletine for treatment of chronic painful diabetic neuropathy. Lancet 1:9–11, 1988.CrossRefGoogle ScholarPubMed
Oskarsson, P, Ljunggren, JG, Lins, PE. Efficacy and safety of mexiletine in the treatment of painful diabetic neuropathy. Diabetes Care 20:1594–7, 1997.CrossRefGoogle ScholarPubMed
Brose, WG, Cousins, MJ. Subcutaneous lidocaine for treatment of neuropathic cancer pain. Pain 45:145–8, 1991.CrossRefGoogle ScholarPubMed
Ellerman, K, Sjogren, P, Banning, A. Trial of intravenous lidocaine on painful neuropathy in cancer patients. Clin J Pain 5:291–4, 1989.CrossRefGoogle Scholar
Bruera, E, Ripamonti, C, Brennis, C. A randomized double-blinded controlled trial of intravenous lidocaine in the treatment of neuropathic cancer pain. J Pain Symptom Manage 7:138–41, 1992.CrossRefGoogle ScholarPubMed
Chong, SF, Bretscher, ME, Mailliard, JA. Pilot study evaluating local anesthetics administered systemically for treatment of pain in patients with advanced cancer. J Pain Symptom Manage 13:112–17, 1997.CrossRefGoogle ScholarPubMed
Galer, BS, Harle, J, Rowbotham, MC. Response to intravenous lidocaine infusion predicts subsequent response to oral mexiletine: a prospective study. J Pain Symptom Manage 12:161–7, 1996.CrossRefGoogle ScholarPubMed
Price, DD, Mayer, DJ, Mao, J. NMDA-receptor antagonists and opioid receptor interactions as related to analgesia and tolerance. J Pain Symptom Manage 19:S7–11, 2000.CrossRefGoogle ScholarPubMed
Okon, T. Ketamine: an introduction for the pain and palliative medicine physician. Pain Physician 10:493–500, 2007.Google ScholarPubMed
Mercadante, S, Lodi, F, Sapio, M. Long-term ketamine infusion in neuropathic cancer pain. J Pain Symptom Manage 10:564–8, 1995.CrossRefGoogle ScholarPubMed
Mercadante, S, Arcuri, E, Tirelli, W. Analgesic effects of intravenous ketamine in cancer patients on morphine therapy: a randomized controlled double-blinded crossover double-dose study. J Pain Symptom Manage 20:246–52, 2000.CrossRefGoogle ScholarPubMed
Fitzgibbon, EJ, Viola, R. Parenteral ketamine as an analgesic adjuvant for severe pain: development and retrospective audit of a protocol for a palliative care unit. J Palliat Med 6:49–56, 2005.CrossRefGoogle Scholar
Jackson, K, Ashby, M, Martin, P. ‘Burst’ ketamine for refractory cancer pain: an open-label audit of 39 patients. J Pain Symptom Manage 22:834–42, 2001.CrossRefGoogle ScholarPubMed
Fine, P. Low-dose ketamine in the management of opioid nonresponsive terminal cancer pain. J Pain Symptom Manage 17:296–300, 1999.CrossRefGoogle ScholarPubMed
Fitzgibbon, EJ, Hall, P, Schroder, C. Low dose ketamine as an analgesic adjuvant in difficult pain syndromes: a strategy for conversion from parenteral to oral ketamine. J Pain Symptom Manage 23:165–70, 2002.CrossRefGoogle ScholarPubMed
Kannan, T, Saxena, A, Bhatnagar, S. Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients. J Pain Symptom Manage 23:60–5, 2002.CrossRefGoogle ScholarPubMed
Dudgeon, D, Bruera, E, Gagnon, B. A phase III randomized double-blinded placebo controlled study evaluating dextromethorphan plus slow-release morphine in chronic cancer pain relief in terminally ill patients. J Pain Symptom Manage 33:365–71, 2007.CrossRefGoogle ScholarPubMed
Pud, D, Eisenberg, E, Spitzer, A. The NMDA receptor antagonist amantadine reduces surgical neuropathic pain in cancer patients: a double-blind, randomized, placebo-controlled trial. Pain 75:349–54, 1998.CrossRefGoogle ScholarPubMed
Sinis, N, Birbaumer, N, Gustin, S. Memantine treatment of complex regional pain syndrome: a preliminary report of six cases. Clin J Pain 23:237–43, 2007.CrossRefGoogle ScholarPubMed
Walker, JM, Hohmann, AG, Martin, WJ. The neurobiology of cannabinoid analgesia. Life Sci 65:665–73, 1999.CrossRefGoogle ScholarPubMed
Walsh, D, Nelson, KA, Mahmoud, FA. Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer 11:137–43, 2003.Google Scholar
Campbell, JA, Tramer, MR, Carroll, D. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 323:1–6, 2001.CrossRefGoogle Scholar
Burns, TL, Ineck, JR. Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain. Ann Pharmacol 40:251–60, 2006.CrossRefGoogle ScholarPubMed
Perez, J, Ribera, MV. Managing neuropathic pain with Sativex: a review of its pros and cons. Expert Opin Pharmacother 9:1189–95, 2008.CrossRefGoogle ScholarPubMed
Body, JJ. Bisphosphonates for malignancy-related bone disease: current status, future developments. Support Care Cancer 14:408–18, 2006.CrossRefGoogle ScholarPubMed
Green, JR. Bisphosphonates: preclinical review. Oncologist 9(Suppl 4):3–13, 2004.CrossRefGoogle ScholarPubMed
Vitte, C, Flisch, H, Guenther, HL. Bisphosphonates induce osteoblasts to secrete inhibitor osteoclast-mediated resorption. Endocrinology 137:2324–33, 1996.CrossRefGoogle ScholarPubMed
Fulfaro, F, Casuccio, A, Ticozzi, C. The role of bisphosphonates: a review of phase III trials. Pain 78:157–69, 1998.CrossRefGoogle ScholarPubMed
Tubiana-Hulin, M, Beuzeboc, P, Mauriac, L, et al. Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastasis [in French]. Bull Cancer 88:701–7, 2001.Google Scholar
McCoskey, EV, Maclennan, IC, Drayson, MT. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. Br J Hematol 100:317–25, 1998.CrossRefGoogle Scholar
Hortobagyi, GN, Thriault, RL, Lipton, A. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 16:2038–44, 1998.CrossRefGoogle ScholarPubMed
Lipton, A, Theriault, RL, Hortobagyi, GN. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma with osteolytic bone metastases: long-term follow-up of 2 randomized, placebo-controlled trials. Cancer 88:1082–90, 2000.3.0.CO;2-Z>CrossRefGoogle ScholarPubMed
Jagdec, SP, Purohito, P, Heatley, S. Comparison of the effect of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Ann Oncol 12:1433–8, 2001.CrossRefGoogle Scholar
Kohno, N, Aogi, K, Minami, H. Zoledronic acid significantly reduces skeletal complications compared to placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23:3314–21, 2005.CrossRefGoogle ScholarPubMed
Saad, F. Treatment of bone complications in advanced prostate cancer: rationale for bisphosphonate use and results of a phase III trial with zoledronic acid. Semin Oncol 29(Suppl 21):19–27, 2002.CrossRefGoogle ScholarPubMed
Rosen, LS, Gordon, D, Tchekmdyian, S. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomised trial. J Clin Oncol 21:3150–7, 2002.CrossRefGoogle Scholar
Rosen, LS, Gordon, D, Kaminski, M. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blinded, comparative trial. Cancer J 7:377–87, 2001.Google ScholarPubMed
Body, JJ, Diel, IJ, Lichinister, MR, et al.; MF 4265 Study Group. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14:1399–405, 2003.CrossRefGoogle Scholar
Body, JJ, Diel, IJ, Bell, R, et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 111:306–12, 2004.CrossRefGoogle ScholarPubMed
Menssen, HD, Sakalova, A, Fontana, A. Effects of long-term intravenous ibandronate on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol 20:2253–9, 2002.CrossRefGoogle ScholarPubMed
Gralow, J, Tripathy, D. Managing metastatic bone pain: the role of bisphosphonates. J Pain Sympt Manage 33:462–72, 2007.CrossRefGoogle ScholarPubMed
Woo, SB, Hellstein, JW, Kalmar, JR. Systematic review: bisphosphonates and osteonecrosis of the jaw. Ann Intern Med 144:753–61, 2006.CrossRefGoogle Scholar
Barnias, A, Kastritis, E, Bamia, C. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23:8580–7, 2005.Google Scholar
Estilo, CL, Poznak, CH, Wiliams, T, et al. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. Oncologist 13:911–20, 2008.CrossRefGoogle ScholarPubMed
Roth, A, Kolaric, K. Analgesic activity of calcitonin in patients with painful osteolytic metastases of breast cancer: results of a controlled randomized study. Oncology 43:283–7, 1986.CrossRefGoogle ScholarPubMed
Blomqvist, C, Elomaa, I, Porkka, L. Evaluation of salmon calcitonin treatment in bone metastases from breast cancer – a controlled trial. Bone 9:45–51, 1988.CrossRefGoogle ScholarPubMed
Martinez-Zapata, MJ, Roque, M, Alonso-Coello, P. Calcitonin for metastatic bone pain. Cochrane Database Syst Rev CD003223, 2006.
Roque, M, Martinez-Zapata, MJ, Alonso-Coello, P. Radioisotopes for metastatic bone cancer. Cochrane Database Syst Rev CD003347, 2003.
Mercadante, S, Casuccio, A, Mangione, S. Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review. J Pain Symptom Manage 33:217–23, 2007.CrossRefGoogle ScholarPubMed
Ripamonti, C, Twycross, R, Baines, M. Clinical practice recommendations for the management of bowel obstruction in patients with end-stage cancer. Support Care Cancer 9:223–33, 2001.CrossRefGoogle ScholarPubMed
Laval, G, Girarder, J, Lassauniere, J. The use of steroids in the management of inoperable intestinal obstruction in terminal cancer patients: do they remove the obstruction?Palliat Med 14:3–10, 2000.CrossRefGoogle ScholarPubMed
Conno, F, Caraceni, A, Zecca, E. Continuous subcutaneous infusion of hyoscine butylbromide reduces secretions in patients with gastrointestinal obstruction. J Pain Symptom Manage 6:484–6, 1991.CrossRefGoogle ScholarPubMed
Ripamonti, C, Mercadante, S, Groff, L. Role of octreotide, scopolamine butylbromide and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial. J Pain Symptom Manage 19:23–34, 2000.CrossRefGoogle ScholarPubMed
Mercadante, S, Ripamonti, C, Casuccio, A. Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. Support Care Cancer 8:188–91, 2000.CrossRefGoogle ScholarPubMed
Mystakidou, K, Tsilika, E, Kalaidopoulou, O. Comparison of octreotide administration vs. conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double-blinded, controlled clinical trial. Anticancer Res 22:1187–92, 2002.Google Scholar
Mercadante, S, Ferrera, P, Villari, P. Aggressive pharmacological treatment for reversing bowel obstruction. J Pain Symptom Manage 28:412–16, 2004.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×